A prospective randomised trial to study the role of levamisole and interferon alfa in an adjuvant therapy with 5-FU for stage III colon cancer by Schippinger, W et al.
A prospective randomised trial to study the role of levamisole and
interferon alfa in an adjuvant therapy with 5-FU for stage III colon
cancer
W Schippinger*,1, M Jagoditsch
2, C Sorre ´
2, M Gnant
3, G Steger
4, H Hausmaninger
5, B Mlineritsch
5,
R Schaberl-Moser
1, HJ Mischinger
6, F Hofbauer
7, P Holzberger
8, M Mittlbo ¨ck
9 and R Jakesz
3 for the
Austrian Breast and Colorectal Cancer Study Group
1Medical Department, Division of Oncology, Graz Medical School, A-8036 Graz, Austria;
2St Veit Hospital, A-9300 St Veit/Glan, Austria;
3Department of
Surgery, Vienna Medical School, A-1090 Vienna, Austria;
4First Medical Department, Division of Oncology, Vienna Medical School, A-1090 Vienna, Austria;
5Third Medical Department of the Private Medical Paracelsus University Salzburg, A-5020 Salzburg, Austria;
6Department of Surgery, Graz Medical
School, A-8036 Graz, Austria;
7Department of Surgery, Oberpullendorf Hospital, A-7350 Oberpullendorf, Austria;
8Department of Surgery, Innsbruck
Medical School, A-6020 Innsbruck, Austria;
9Core Unit for Medical Statistics and Informatics, Vienna Medical School, A-1090 Vienna, Austria
The purpose of this trial was to examine the efficacy of the addition of levamisole (LEV) or interferon alfa (IFN) to an adjuvant
chemotherapy with 5-fluorouracil (5-FU) in patients with stage III colon cancer. According to a 2 2 factorial study design, 598
patients were randomly assigned to one of four adjuvant treatment arms. Patients in arm one received 5-FU weekly for 1 year,
patients in arm two 5-FU plus LEV, in arm three 5-FU plus IFN and patients in arm four 5-FU, LEV and IFN. The relative risk of relapse
and the relative risk of death were significantly higher for patients treated with LEV compared with those without LEV treatment (HR
1.452, 95% CI 1.135–1.856, P¼0.0028; HR 1.506, 95% CI 1.150–1.973, P¼0.0027, respectively). No significant impact on survival
was observed for therapy with IFN in the univariate analysis. The addition of LEV to adjuvant 5-FU significantly worsened the
prognosis of patients with stage III colon cancer. Interferon alfa had no significant influence on survival when combined with adjuvant
5-FU, but increased the toxicity of therapy substantially.
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Colorectal cancer is the second most common malignant
disease in developed countries (Parkin et al, 2001). About 50%
of patients with colorectal cancer who undergo surgical treatment
subsequently develop recurrent disease ultimately leading to
incurability. Adjuvant chemotherapy containing 5-fluorouracil
(5-FU) after complete surgical removal of the primary tumour
has been shown in randomised trials to decrease the risk of
disease relapse (Wolmark et al, 1988; Laurie et al, 1989). Based on
reports suggesting a possible benefit of combining 5-FU with
levamisole (LEV), an anthelmintic drug with immunomodulatory
activity, a large Intergroup trial was launched in 1984 comparing
5-FU plus LEV for 1 year with observation in patients with
curatively resected stage III colon cancer. 5-Fluorouracil with LEV
reduced the risk of cancer recurrence by 41% and the overall
death rate by 33% (Moertel et al, 1990). In conclusion of these
results, 5-FU and LEV were considered to be standard adjuvant
treatment for stage III colon cancer for several years (NIH, 1990).
However, other authors failed to show a benefit by adding LEV
to adjuvant 5-FU chemotherapy (Sertoli et al, 1987), and LEV
as a single-agent therapy has been shown to be ineffective as
adjuvant therapy (Arnaud et al, 1989). In addition, the combi-
nation of LEV with 5-FU in advanced colon cancer was shown
not to be superior to 5-FU single-agent therapy (Buroker et al,
1985). At the time the present study was initiated, combina-
tion of LEV and 5-FU was considered to be standard therapy
to eliminate minimal residual disease. Consequently, this trial
was designed to evaluate this combination treatment in compa-
rison with an experimental approach in patients with stage III
colon cancer.
One way to enhance the antitumour activity of 5-FU was the
implementation of interferon alfa (IFN) in treatment strategies of
colorectal cancer. Interferon alfa as an immunomodulatory
cytokine had been shown to increase the cytotoxic activity of
5-FU in human cancer cell lines (Wadler et al, 1990). Several
clinical trials confirmed an increased responsiveness by addition
of IFN to 5-FU in the treatment of metastatic colon cancer (Wadler
et al, 1989, 1991). According to these promising data, the second
aim of the present study was to examine the efficacy of IFN plus
5-FU as adjuvant therapy for stage III colon cancer in a 2 2
factorial study design.
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sMATERIALS AND METHODS
This multicentre trial was initiated by the Austrian Breast and
Colorectal Cancer Study Group (ABCSG) and involved 41
participating hospitals. The protocol was approved by the ethics
committees of the participating institutions. Enrolment of patients
began in October 1991 and was completed in April 1999.
Patient selection
To be eligible, patients had to fulfil the following inclusion criteria:
histologically proven carcinoma of the colon with lymph node
metastasis (stage III tumour according to the International Union
Against Cancer); potentially curative resection without gross or
microscopic evidence of residual disease; age between 18 and 80
years; WHO performance status of 0 or 1; absence of severe
concomitant disease and other malignancies; and adequate bone
marrow function. The following were considered as exclusion
criteria: prior or concomitant chemotherapy, immunotherapy and
radiotherapy, carcinoma of the rectum defined as tumour below
the anatomical rectosigmoidal border line or within 16cm from
the anal verge measured by a nonflexible rectoscope. Other
exclusion criteria were the presence of metastasis or a time period
of more than 42 days from surgery to start of adjuvant therapy.
Written informed consent was obtained from all patients
participating in this trial.
Site visits were performed in regular intervals to check the
original data concerning eligibility and to review the documented
chemotherapy and follow-up data.
Surgical treatment
A tumour of the caecum, the ascending colon or the hepatic flexure
was resected with a right hemicolectomy with resection of the right
colic artery and the ileocolic artery. A tumour of the colon
transversum was treated by resection of the appropriate part of the
colon including the hepatic and splenic flexure. Carcinomas of the
descending colon were resected by a left hemicolectomy including
the left colic artery. Finally, sigmoid tumours were treated by a
sigmoid resection including the inferior mesenteric blood vessels.
The resection of at least seven regional lymph nodes was
recommended.
Randomisation and stratification procedures
Patients were stratified by sex, age (p65 vs 465–80 years),
tumour size (T1 vs T2 vs T3 vs T4), number of involved lymph
nodes (p3 vs 43 lymph nodes) and tumour differentiation (G1/2
vs G3/4). Randomisation was performed by computer, assigning
the patients according to a 2 2 factorial study design to one of
four postoperative treatment arms: (1) 5-FU, (2) 5-FU plus
LEV, (3) 5-FU plus IFN and (4) 5-FU plus LEV plus IFN according
to the method of Pocock and Simon (1975), which marginally
balances the following criteria: sex, age (p65 vs 465–80 years),
tumour size (T1 vs T2 vs T3 vs T4), number of involved lymph
nodes (p3 vs 43 lymph nodes), tumour differentiation (G1/2 vs
G3/4) and state.
Schedules of chemotherapy administration
Adjuvant chemotherapy was required by the trial protocol to be
started within 42 days after tumour resection. In treatment arm 1,
adjuvant therapy consisted of 5-FU 450mgm
 2 as an intravenous
bolus given initially on five consecutive days and then once weekly,
starting on day 28 for 48 weeks (¼52 weeks of therapy). Patients
in treatment arm 2 received 5-FU as in arm 1 and additionally LEV
50mg orally three times a day for three consecutive days (days
1–3) every 14 days. In arm 3, patients received 5-FU as in arm 1
and interferon alfa-2C (Berofor
s, Boehringer Ingelheim GmbH,
Germany) at a dose of 3.5 10
6U subcutaneously three times a
week (Monday, Wednesday, Friday) for 52 weeks. Arm 4 consisted
of 5-FU plus LEV in the same schedule as in arm 2 and of IFN
3.5 10
6U subcutaneously three times a week (Monday, Wednes-
day, Friday) for 52 weeks.
In all four treatment arms, dose modifications were required for
haematologic or other severe toxicity. According to the protocol,
the 5-FU dosage was reduced by 25% when patients developed
leucopenia (3.0–3.5 10
9l
 1) and/or thrombocytopenia
(o100 10
9 and 475.10
9l
 1). The dose was reduced by 50%,
when thrombocyte counts decreased to 50 10
9–75 10
9l
 1.I n
case of more severe leucopenia (o3.0 10
9l
 1) and/or thrombo-
cytopenia (o50 10
9l
 1), treatment was delayed for 1 week.
Follow-up
During the first year after randomisation (¼treatment period),
patients were evaluated every 3 months, during years 2–5 every 6
months and thereafter, once yearly until year 10 after randomisa-
tion. A physical examination with evaluation of body weight and
performance status, determination of blood count, serum liver
function parameters, carcinoembryonic antigen (CEA) and tests
for occult blood in stool, as well as chest radiography and
ultrasonography of the liver were performed at each follow-up
visit. Colonoscopy was required during the first 5 years every
6 months, then once a year.
Statistical methods
The trial was planned as 2 2 factorial design with four arms (LEV
vs no LEV and IFN vs no IFN). It was designed to detect a
difference in 5-year survival rate for each factor of 12% (59–71%)
with a power of 85% and a two-sided significance level of 0.05, so
that approximately 200 patients would be recruited for 3 years and
followed-up for another 4 years or equivalently 225 observed
deaths.
The intention-to-treat analysis included all eligible patients for
whom complete baseline data were available. All patient data were
collected at the study group’s central data office and processed and
analysed applying SAS software (SAS Institute, Cary/NC, USA).
Distribution of prognostic factors to the treatment arms was
described with frequencies for categorical variables and with
medians for continuous data and tested with the w
2-test and
Kruskal–Wallis test, respectively.
Overall survival (OS) was defined as the time between date of
randomisation of primary colon cancer until date of last visit or
date of death, independent of the cause of death. Disease-free
survival (DFS) was defined as time from randomisation to either
recurrence of colon cancer, occurrence of metastases, occurrence
of a second primary cancer, or death without evidence of
recurrence or a second primary tumour, or date of last visit.
Overall survival and DFS were estimated and graphically
presented according to the method of Kaplan and Meier (1958).
Differences between curves were assessed by the Mantel log-rank
test for censored survival data (Mantel, 1966). The Cox propor-
tional hazards model (Cox, 1972) was used to assess the prognostic
values of treatment, sex, age, lymph node status, tumour grading,
tumour stage, tumour localisation and number of surgically
removed lymph nodes in univariate and multiple analyses and
quantifies their effect by hazard ratios. Corresponding 95%
confidence intervals are also given. Furthermore, it was applied
to assess interactions between treatment and the other covariates
and to detect nonproportionality. A Cox regression model with the
time-dependent factor was modelled to assess the effect of the
cumulative 5-FU dose, which increases with time from the first to
the last treatment delivery. All P-values given are two-sided.
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Patient characteristics
A total of 598 patients entered this prospective randomised trial. A
total of 22 erroneously randomised patients (3.7%) were found to
be ineligible and were therefore not included in the analysis. Four
patients were removed from the statistical analysis for lack of any
baseline or follow-up data. Statistical analyses were performed
with the data of the remaining 572 eligible patients according to
the intention-to-treat principle. Baseline patient and tumour
characteristics are reported in Table 1. The patient and tumour
characteristics were well balanced between the four treatment
arms. The median follow-up time for the study population was
84.3 months and 50% of the patients had a follow-up time of
65.2–108.2 months.
Treatment adherence and delivered 5-FU dose
Adjuvant therapy as planned in the protocol was prematurely
discontinued without evidence of tumour relapse in 25 patients
(17.2%) of the 5-FU single-agent group, in 29 patients (20.7%) of the
5-FU plus LEV group, in 52 patients (36.6%) of the 5-FU plus IFN
group and in 72 patients (49.7%) of the 5-FU/LEV/IFN triple-agent
group. In most of the cases, the reasons for treatment discontinua-
tion were toxicity and the patients’ wish to discontinue therapy. The
median, actually delivered 5-FU dose (5-FU dose given in grams per
square metre) cumulated over time was 22.397gm
 2 in treatment
arm 1, 21.600gm
 2 in arm 2, 17.118gm
 2 in therapy arm 3 and
13.500gm
 2 in arm 4.
The median cumulatively delivered 5-FU dose was significantly
lower in the therapy arms including LEV than in the treatment
arms without LEV (17.953 vs 20.828gm
 2, P¼0.0055) and also
significantly lower in the therapy arms including IFN compared to
the treatment arms without IFN (15.647
2 vs 22.050gm
 2,
Po0.0001).
As older patients may tend to have lower tolerability for
treatment combinations, the association between age and cumula-
tively delivered 5-FU dose (o80 vs X80% of planned dose) was
investigated in a cross-table. The results showed a trend to higher
5-FU dose for younger patients in treatment arms 1 and 2, where
no IFN was applied. The two arms with IFN treatment (groups 3
and 4) showed a higher rate of patients with lower cumulatively
delivered 5-FU dose; however, lower 5-FU dose seemed not to be
related to age of patients.
Tumour relapse and disease-free survival
To date, 259 patients have relapsed. Tumour relapse was
documented in 136 of 285 patients (47.7%) in the therapy
arms containing LEV (treatment arms 2 and 4), in 113 of 287
patients (39.4%) in the therapy arms not containing LEV (arms 1
and 3), in 134 of 287 patients (46.7%) treated with IFN (arms 3
and 4) and in 125 of 285 patients (43.8%) not treated with IFN
(arms 1 and 2).
In univariate analyses, the relative risk of relapse in the patient
cohort treated with LEV (treatment arms 2 and 4) was significantly
higher than in the patient group that had not received LEV (arms 1
and 3) (HR 1.452, 95% CI 1.135–1.856, log-rank test: P¼0.0028).
There was no statistically significant difference in the relative risk
of relapse between the patient group treated with IFN and the
group without IFN treatment (HR 1.019, 95% CI 0.798–1.300, log-
rank test: P¼0.8826).
Consequently, DFS was significantly shorter for patients treated
with LEV compared to patients who had not received LEV.
No significant difference in DFS was observed between patients
treated with IFN and patients treated without IFN.
Kaplan–Meier curves for DFS are shown in Figures 1 and 3.
Overall survival
Altogether, 217 of 572 eligible patients have died: 126 of 285
patients (44.2%) in the therapy arms containing LEV (treatment
arms 2 and 4), 91 of 287 patients (31.7%) in the therapy arms not
containing LEV (arms 1 and 3), 114 of 287 patients (39.7%) treated
with IFN (arms 3 and 4) and 103 of 285 patients (36.1%) not
treated with IFN (arms 1 and 2).
Univariate analyses revealed that patients treated with LEV had
a significantly higher relative risk of death compared to those
Table 1 Clinical and pathological characteristics by treatment arms
5-FU (%) 5-FU+LEV (%) 5-FU+IFN (%) 5-FU+LEV+IFN (%) P-value
Number of patients 145 140 142 145
Median age (years) 63.0 62.6 62.9 63.2 0.7249
Male/female 51.7/48.3 50.7/49.3 51.4/48.6 50.3/49.7 0.9953
T category 0.9897
T1 2.1 0.7 1.4 0.7
T2 8.3 7.9 9.2 9.7
T3 75.2 75.0 73.2 73.8
T4 14.5 16.4 16.2 15.8
N category 0.9991
N1 55.8 55.0 54.9 56.5
N2 29.0 29.3 31.0 28.3
N3 15.2 15.7 14.1 15.2
Grading 0.9616
G1 and G2 67.6 69.1 70.4 69.7
G3 and G4 32.4 30.9 29.6 30.3
Location of tumour 0.4467
Caecum and right colon 30.3 32.9 25.4 29.0
Left colon and sigmoid 46.9 46.4 48.6 54.5
Flexures and transverse colon 22.8 20.7 26.1 16.5
5-FU¼5-fluorouracil; LEV¼levamisole; IFN¼interferon alfa.
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1.973, P¼0.0027).
No significant difference in the relative risk of death was
observed between the patient group treated with IFN and the
group treated without IFN (HR 1.046, 95% CI 0.802–1.366,
P¼0.738).
Considering these data, it follows that patients treated with LEV
had a significant disadvantage in OS compared to those patients
who did not receive LEV.
There was no significant difference in OS between patients
treated with IFN and the patients without IFN therapy.
Kaplan–Meier curves for OS are presented in Figures 2 and 4.
Multiple analyses of prognostic factors
Cox regression analysis revealed age, sex, tumour size, the number
of metastatic lymph nodes and treatment with LEV as significant
prognostic factors for DFS. Therapy with IFN, grading and tumour
localisation had no significant impact on DFS in the multiple
analysis.
With regard to OS, sex, tumour size, the number of metastatic lymph
nodes and again treatment with LEV were found to be significant
prognostic variables. Therapy with IFN, grading, tumour localisation
and age demonstrated no significant impact on OS in the Cox model.
T h er e s u l t so ft h em u l t i p l ea n a l y s e sa r es h o w ni nT a b l e s2a n d3 .
An additional Cox analysis including the cumulatively delivered
5-FU dose per patient demonstrated this parameter to have a
statistically significant impact on OS (Po0.0001), but no
significant influence on DFS (P¼0.1232). Adjusting for the
cumulative 5-FU dose in the multiple analyses for DFS, the effect
of IFN remained nonsignificant and the effect of LEV also
remained approximately the same. Analogous multiple analyses
for OS revealed that the effect of IFN was significant (HR 0.730,
P¼0.0347). The effect of LEV was slightly weaker (HR 1.334,
P¼0.0418) when adjusted for the cumulative 5-FU dose but
remained statistically significant (all patients were considered in
these analyses according to the intention-to-treat principle). When
considering only patients who received at least one therapy cycle,
three patients were excluded from the analyses and the effect of
LEV on OS again remained significant.
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sAnalysing interaction terms with respect to time, the multiple
model revealed treatment with IFN as a time-dependent prognostic
factor for DFS and OS, indicating that therapy with IFN reduces
the risk of relapse and the risk of death temporarily, but not over
the entire follow-up period (see Figures 3 and 4).
Toxicity
Grade 3 and 4 toxicities were documented during adjuvant therapy
in 11.2% of the patients in the 5-FU single-agent arm, in 21.5% of
the patients treated with 5-FU/LEV, in 26.7% of the patients in the
5-FU/IFN arm and in 40.4% of the patients treated in the 5-FU/
LEV/IFN arm.
The distribution of grade 3 and 4 toxic effects is shown in
Table 4.
DISCUSSION
At the time of initiation of this trial, the combination of 5-FU with
LEV was considered as the standard adjuvant treatment of stage III
colon cancer. However, in the final phase of recruitment to this
trial, data from other studies showed that neither LEV nor IFN is of
benefit in the adjuvant treatment of colon cancer. Final analysis
data of the Intergroup trial INT 0089 suggested 5-FU plus
leucovorin for 6 months to be preferable over 12 months of 5-
FU plus LEV for reasons of toxicity, costs and patients convenience
(Haller et al, 1998). The NSABP trial C-04 compared the efficacy of
5-FU plus leucovorin with 5-FU plus LEV and with the triple
combination of 5-FU plus leucovorin plus LEV. The study
demonstrated a statistically significant prolongation of DFS in
favour of 5-FU plus leucovorin compared to 5-FU plus LEV, but no
significant difference between these two treatment arms in terms
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sof OS. The comparison between patients treated with 5-FU plus
leucovorin and those who received 5-FU plus leucovorin plus LEV
showed no difference for either DFS or OS (Wolmark et al, 1999).
The NSABP protocol C-05 evaluated the efficacy of the addition of
interferon alfa-2a to 5-FU and leucovorin in the adjuvant
treatment of colon cancer. The results of this trial showed no
significant difference either in DFS or in OS for the IFN arm
(Wolmark et al, 1998). Owing to the absence of significant
differences in OS in these trials examining the role of LEV and IFN
in the adjuvant setting of colon cancer, continuation of accrual in
the present trial was considered as ethically justifiable until the end
of the accrual period in 1999.
In this trial, it was documented for the first time that the
combination of LEV with 5-FU as adjuvant treatment of stage III
colon cancer is significantly inferior in terms of DFS and OS
compared to a therapy with 5-FU alone. Owing to the finding that
patients in the LEV-containing therapy arms received less
cumulative 5-FU, the unfavourable effect of LEV could be assumed
to be caused by the lower 5-FU dose only. However, the multiple
analysis adjusting for differences in the cumulatively delivered 5-
FU dose in the treatment groups caused only a minor change of
observed hazard ratio for the therapy effect of LEV. Thus, it can be
ruled out that the observed differences in DFS and OS are
exclusively a consequence of different 5-FU doses in the treatment
arms. Levamisole affects survival independently of the delivered
cumulative 5-FU dose. These findings contribute to assess the
efficacy of LEV in 5-FU-based adjuvant therapy, since the
Intergroup trial published by Moertel et al (1990), which led to
the NIH consensus suggesting 5-FU and LEV as standard
treatment for stage III colon cancer, compared 5-FU plus LEV
with observation and with LEV alone. The Intergroup trial
revealed, for the single-agent LEV arm, an identical OS to no
adjuvant therapy. Another study addressing the role of LEV in
colon cancer, the Quick and Simple and Reliable (QUASAR) trial,
investigated a possible survival benefit by using a higher dose of
folinic acid or by addition of LEV to 5-FU and folinic acid and
found no survival benefit from LEV (QUASAR Collaborative
Group, 2000). Patients treated with LEV had an even higher,
although statistically not significant, odds ratio for disease
recurrence and death compared to patients without LEV therapy.
The observed trend to deterioration of prognosis by addition of
LEV in the QUASAR trial is not concordant with the findings of
our study, which shows a significantly detrimental effect of LEV in
5-FU-based adjuvant therapy of colon cancer. A possible explana-
tion for the more distinct survival disadvantage for the LEV arm in
the present study could be the higher 5-FU dose density in a
fraction of the QUASAR study population, whereas the dose
density of LEV was the same as in the present study.
In view of the findings of the present study, an antagonising
effect of LEV on 5-FU can be suggested. Furthermore, the findings
of this trial correlate very well with the results of a recently
published preclinical study, which found that LEV did not only
lack a significant growth inhibitory effect as a single agent in colon
cancer cell lines, but also antagonised 5-FU-induced tumour
growth inhibition when combined with this cytostatic agent
(Wiebke et al, 2003).
The results of the present study imply that the addition of LEV
to 5-FU in the adjuvant treatment of colon cancer has an
unfavourable effect on patient prognosis and should therefore
not be considered as a possible adjuvant treatment option.
A smaller trial comparing an adjuvant therapy with 5-FU plus
LEV for 1 year with 5-FU plus folinic acid, administered for either
6 or 12 months, showed that 6 or 12 months of treatment with 5-
FU plus folinic acid is equivalent to 12 months with 5-FU plus LEV
(Dencausse et al, 2002).
Another study comparing 5-FU plus leucovorin with 5-FU plus
LEV, both for 1 year as adjuvant therapy in patients with resected
stage III colon cancer, showed a significant superiority of the 5-FU
plus leucovorin arm in terms of DFS and OS (Arkenau et al, 2003).
The INTACC trial investigating whether the addition of
leucovorin to the combination of 5-FU plus LEV improves survival
in patients with Dukes’ B and C colon cancer showed no statistical
difference in DFS and OS between the 5-FU/LEV and the 5-FU/
LEV/leucovorin treatment arms (Di Costanzo et al, 2003).
The second goal of the present study was to examine the effect of
IFN in a 5-FU-based adjuvant therapy for stage III colon cancer.
Table 2 Multiple analysis: evaluation of prognostic factors for DFS
HR 95% CI P-value
Age 1.134 1.011–1.273 0.0325
Sex 1.331 1.036–1.711 0.0255
Tumour size 1.432 1.119–1.831 0.0043
Number of metastatic lymph nodes 1.369 1.058–1.771 0.0169
Histopathological grading 1.241 0.950–1.621 0.1132
Location of tumour 0.8169
Left colon and sigmoid 1.095 0.814–1.472
Flexures and transverse colon 1.097 0.766–1.571
Treatment with LEV 1.430 1.115–1.835 0.0049
Treatment with IFN 0.942 0.736–1.206 0.6364
For the HR, the reference category for categorical covariates was female for sex, p3
metastatic lymph nodes for number of metastatic lymph nodes, G1/G2 for
histopathological grading, caecum and right colon for location of tumour, no LEV
for treatment with LEV and no IFN for treatment with IFN. DFS¼disease-free
survival; LEV¼levamisole; IFN¼interferon alfa.
Table 3 Multiple analysis: evaluation of prognostic factors for OS
HR 95% CI P-value
Age 1.011 0.998–1.025 0.0923
Sex 1.452 1.103–1.912 0.0078
Tumour size 1.659 1.266–2.174 0.0002
Number of metastatic lymph nodes 1.417 1.069–1.879 0.0155
Histopathological grading 1.232 0.920–1.650 0.1623
Location of tumour 0.7833
Left colon and sigmoid 1.121 0.812–1.548
Flexures and transverse colon 1.065 0.715–1.585
Treatment with LEV 1.460 1.110–1.920 0.0069
Treatment with IFN 0.975 0.744–1.278 0.8539
For the HR, the reference category for categorical covariates was female for sex, p3
metastatic lymph nodes for number of metastatic lymph nodes, G1/G2 for
histopathological grading, caecum and right colon for location of tumour, no LEV
for treatment with LEV and no IFN for treatment with IFN. OS¼overall survival;
LEV¼levamisole; IFN¼interferon alfa.
Table 4 Patients with grade 3 and 4 toxicities in the four treatment arms
5-FU
(%)
5-FU+
LEV (%)
5-FU+
IFN (%)
5-FU+LEV+
IFN (%) P-value
Nausea 3.5 6.5 3.6 8.2 0.2197
Diarrhoea 3.5 3.6 2.9 3.4 0.9885
Stomatitis 0 2.2 0.7 1.4 0.2870
Fever 0 0.7 2.2 4.1 0.0331
Leucopenia 0.7 1.4 3.6 11.6 o0.0001
Thrombopenia 0.7 1.4 2.2 1.4 0.8806
Alopecia 0 0.7 0.7 1.4 0.7606
Other toxic effects 2.8 5.0 10.8 8.9 0.0488
5-FU¼5-fluorouracil; LEV¼levamisole; IFN¼interferon alfa.
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within the first years of follow-up for patients treated with IFN,
this early benefit in terms of DFS and OS is counterbalanced by a
higher number of disease relapses and deaths at later periods of
follow-up. Higher toxicity and a higher frequency of premature
therapy cessations resulted in a significantly lower cumulative 5-
FU delivery in the IFN treatment arms, which could be a reason for
the missing effect of IFN on DFS and OS. In fact, the multiple
model adjusting for the delivered 5-FU dose demonstrates a
significantly positive impact of IFN on OS, but not on DFS. As 5-
FU dose is different between therapy groups, it cannot be ruled out
that patients receiving a higher 5-FU dose are a selected group with
good prognostic factors. Thus, the improved OS hazard ratio for
the IFN treatment group in the 5-FU adjusted model could be
explained by age or other unobserved nontreatment-related
prognostic factors also. These findings confirm the results of
other trials that the addition of IFN to 5-FU does not confer a
survival benefit (Wolmark et al, 1998).
Frequency of grade 3 and 4 toxicities was increased in therapy
arms including LEV or IFN. The highest rate of severe toxicities
was documented within the patient group treated with the triple-
agent combination. Premature discontinuation of therapy was
most frequent in the treatment arms containing IFN; the highest
number of therapy cessations was observed in the 5-FU/LEV/IFN
arm.
Summarising the results of this study, neither LEV nor IFN
showed efficacy in a 5-FU-based adjuvant therapy for stage III
colon cancer.
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Appendix A
Apart from the authors of this article, members of the Austrian
Breast and Colorectal Cancer Study Group participating in this
trial included the following: E Andritsch, H Bacher, T Bauernhofer,
A Berger, O Bo ¨ckl, K Czerwenka, D Depisch, W Draxler,
P Dubsky, A El-Shabrawi, J Freisinger, B Gebhard, P Go ¨tzinger,
T Gru ¨nberger, K Haider, M Hanak, B Hartmann, H Hauser, J
Hebenstreit, E Hell, G Hofmann, D Hussian, G Jatzko, C Kainz, D
Kandioler, A Kasparek, R Kolb, P Konstantiniuk, G Kosina,
P Krippl, L Kronberger, I Kuss, W Kwasny, M Lang, G Locker,
H Ludwig, H Luschnik, K Mach, P Mayer, R Menzel, G Michlmayr,
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Sevelda, M Smola, H Spoula, P Steindorfer, H Sto ¨ger, S Taucher,
C Tausch, J Tschmelitsch, G Tschurtschenthaler, M Umlauft,
N Vavra, P Wagner, G Wahl, M Wehrschu ¨tz, C Wenzel and
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